Information about Leqvio (Inclisiran)
Leqvio is a medication that utilizes RNA interference technology to lower cholesterol levels. It is specifically designed to target and reduce low-density lipoprotein cholesterol (LDL-C) in patients at high risk for cardiovascular disease.
Product Highlights
- Treatment of adult patients with heterozygous familial hypercholesterolemia (HeFH) or atherosclerotic cardiovascular disease (ASCVD) who require additional LDL-C lowering.
Key Ingredient
Key Benefits
- Significant lowering of LDL cholesterol levels, helping to reduce cardiovascular risk.
- Administered just twice a year after the initial doses, making it easier for patients to adhere to treatment.
- Typically well-tolerated and associated with a favorable safety profile.
Direction of Use
- Administer an initial dose, followed by a second dose at 3 months, and then every 6 months thereafter.
- Administered via subcutaneous injection in the abdomen, thigh, or upper arm.
Safety Concerns
- May involve reactions at the injection site, fatigue, and headache.
- Rarely, can cause allergic reactions or liver enzyme abnormalities.
Avoid Leqvio (Inclisiran) If
- You have a known allergy to inclisiran or any other components of the formulation.
- You are pregnant, planning to become pregnant, or breastfeeding without consulting a healthcare professional.
- You have severe liver disease or significant liver dysfunction without medical evaluation.
